211 related articles for article (PubMed ID: 32027517)
1. Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study.
Zhu A; Bews H; Cheung D; Nagalingam RS; Mittal I; Goyal V; Asselin CY; Kirkpatrick IDC; Czubryt MP; Jassal DS
Can J Physiol Pharmacol; 2020 Jul; 98(7):459-465. PubMed ID: 32027517
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
[TBL] [Abstract][Full Text] [Related]
3. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
[TBL] [Abstract][Full Text] [Related]
4. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
[TBL] [Abstract][Full Text] [Related]
6. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
[TBL] [Abstract][Full Text] [Related]
7. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.
Latif SR; Nguyen VQ; Peters DC; Soufer A; Henry ML; Grunseich K; Testani J; Hur DJ; Huber S; Mojibian H; Dicks D; Sinusas AJ; Meadows JL; Papoutsidakis N; Jacoby D; Baldassarre LA
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1309-1318. PubMed ID: 30790116
[TBL] [Abstract][Full Text] [Related]
8. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Doesch C; Sperb A; Sudarski S; Lossnitzer D; Rudic B; Tülümen E; Heggemann F; Schimpf R; Schoenberg SO; Borggrefe M; Papavassiliu T
Arch Cardiovasc Dis; 2015; 108(6-7):356-66. PubMed ID: 25863428
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
Chacko BR; Karur GR; Connelly KA; Yan RT; Kirpalani A; Wald R; Jimenez-Juan L; Jacob JR; Deva DP; Yan AT
Indian Heart J; 2018; 70(1):75-81. PubMed ID: 29455792
[TBL] [Abstract][Full Text] [Related]
10. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
[TBL] [Abstract][Full Text] [Related]
11. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
[TBL] [Abstract][Full Text] [Related]
12. Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction.
Zhu Y; Park EA; Lee W; Kim HK; Chu A; Chung JW; Park JH
Eur Radiol; 2015 Apr; 25(4):1190-200. PubMed ID: 25597022
[TBL] [Abstract][Full Text] [Related]
13. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
[TBL] [Abstract][Full Text] [Related]
14. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
Nucifora G; Muser D; Gianfagna P; Morocutti G; Proclemer A
Int J Cardiovasc Imaging; 2015 Dec; 31(8):1603-10. PubMed ID: 26210792
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
He D; Ye M; Zhang L; Jiang B
Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
[TBL] [Abstract][Full Text] [Related]
16. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
[TBL] [Abstract][Full Text] [Related]
17. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.
Maron MS
J Cardiovasc Transl Res; 2009 Dec; 2(4):415-25. PubMed ID: 20560000
[TBL] [Abstract][Full Text] [Related]
18. Left Atrial Performance in the Course of Hypertrophic Cardiomyopathy: Relation to Left Ventricular Hypertrophy and Fibrosis.
Kowallick JT; Silva Vieira M; Kutty S; Lotz J; Hasenfu G; Chiribiri A; Schuster A
Invest Radiol; 2017 Mar; 52(3):177-185. PubMed ID: 27741021
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
